$DMAC
DiaMedica Therapeutics Inc.

2021 Q1 Form 10-Q Financial Statement

#000143774921010912 Filed on May 05, 2021

View on sec.gov

Income Statement

Concept 2021 Q1 2020 Q1
Revenue $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $1.210M $1.020M
YoY Change 18.63% 25.93%
% of Gross Profit
Research & Development $2.406M $1.349M
YoY Change 78.35% -48.25%
% of Gross Profit
Depreciation & Amortization $6.000K $6.000K
YoY Change 0.0% 0.0%
% of Gross Profit
Operating Expenses $2.406M $1.349M
YoY Change 78.35% -60.57%
Operating Profit -$3.619M -$2.404M
YoY Change 50.54% -29.73%
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net $4.000K -$12.00K
YoY Change -133.33% -93.26%
Pretax Income -$3.615M -$2.416M
YoY Change 49.63% -25.5%
Income Tax $7.000K $9.000K
% Of Pretax Income
Net Earnings -$3.622M -$2.425M
YoY Change 49.36% -25.43%
Net Earnings / Revenue
Basic Earnings Per Share -$0.19
Diluted Earnings Per Share -$192.9K -$185.4K
COMMON SHARES
Basic Shares Outstanding 18.77M 14.14M
Diluted Shares Outstanding

Balance Sheet

Concept 2021 Q1 2020 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $23.43M $12.60M
YoY Change 85.94% -8.42%
Cash & Equivalents $3.329M $3.300M
Short-Term Investments $20.10M $9.300M
Other Short-Term Assets $460.0K $540.0K
YoY Change -14.81% 80.0%
Inventory
Prepaid Expenses
Receivables $337.0K $985.0K
Other Receivables
Total Short-Term Assets $24.20M $14.17M
YoY Change 70.81% -5.21%
LONG-TERM ASSETS
Property, Plant & Equipment $75.00K $60.00K
YoY Change 25.0% -33.33%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $161.0K $200.0K
YoY Change -19.5% -63.64%
TOTAL ASSETS
Total Short-Term Assets $24.20M $14.17M
Total Long-Term Assets $161.0K $200.0K
Total Assets $24.36M $14.37M
YoY Change 69.55% -7.29%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $689.0K $444.0K
YoY Change 55.18% -35.18%
Accrued Expenses $420.0K $435.0K
YoY Change -3.45% -36.59%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due $10.00K $10.00K
YoY Change 0.0% 0.0%
Total Short-Term Liabilities $1.178M $935.0K
YoY Change 25.99% -34.39%
LONG-TERM LIABILITIES
Long-Term Debt $10.00K $10.00K
YoY Change 0.0% -50.0%
Other Long-Term Liabilities $30.00K $100.0K
YoY Change -70.0% -33.33%
Total Long-Term Liabilities $33.00K $107.0K
YoY Change -69.16% -34.36%
TOTAL LIABILITIES
Total Short-Term Liabilities $1.178M $935.0K
Total Long-Term Liabilities $33.00K $107.0K
Total Liabilities $1.211M $1.042M
YoY Change 16.22% -34.38%
SHAREHOLDERS EQUITY
Retained Earnings -$72.53M -$59.04M
YoY Change 22.85% 19.96%
Common Stock $0.00 $0.00
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $23.15M $13.32M
YoY Change
Total Liabilities & Shareholders Equity $24.36M $14.37M
YoY Change 69.55% -7.29%

Cashflow Statement

Concept 2021 Q1 2020 Q1
OPERATING ACTIVITIES
Net Income -$3.622M -$2.425M
YoY Change 49.36% -25.43%
Depreciation, Depletion And Amortization $6.000K $6.000K
YoY Change 0.0% 0.0%
Cash From Operating Activities -$4.313M -$2.978M
YoY Change 44.83% -4.98%
INVESTING ACTIVITIES
Capital Expenditures $9.000K $2.000K
YoY Change 350.0%
Acquisitions
YoY Change
Other Investing Activities $0.00 -$5.300M
YoY Change -100.0% -51.51%
Cash From Investing Activities -$9.000K -$5.301M
YoY Change -99.83% -51.49%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $0.00 $8.500M
YoY Change -100.0%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities $242.0K 7.696M
YoY Change -96.86% -384900.0%
NET CHANGE
Cash From Operating Activities -$4.313M -2.978M
Cash From Investing Activities -$9.000K -5.301M
Cash From Financing Activities $242.0K 7.696M
Net Change In Cash -$4.080M -583.0K
YoY Change 599.83% -95.85%
FREE CASH FLOW
Cash From Operating Activities -$4.313M -$2.978M
Capital Expenditures $9.000K $2.000K
Free Cash Flow -$4.322M -$2.980M
YoY Change 45.03% -4.91%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2021Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2021Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001401040
CY2021Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2021Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2021Q1 dei Entity Ex Transition Period
EntityExTransitionPeriod
true
CY2021Q1 dei Trading Symbol
TradingSymbol
dmac
CY2021Q1 dmac Accrued Clinical Study Costs Current
AccruedClinicalStudyCostsCurrent
237000
CY2021Q1 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2021Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2021Q1 dei Entity Registrant Name
EntityRegistrantName
DiaMedica Therapeutics Inc.
CY2021Q1 dei Entity Small Business
EntitySmallBusiness
true
CY2020Q4 dmac Accrued Clinical Study Costs Current
AccruedClinicalStudyCostsCurrent
13000
CY2021Q1 dmac Accrued Research And Professional Fees Current
AccruedResearchAndProfessionalFeesCurrent
143000
CY2020Q4 dmac Accrued Research And Professional Fees Current
AccruedResearchAndProfessionalFeesCurrent
360000
CY2021Q1 dmac Accrued Taxes And Other Liabilities Current
AccruedTaxesAndOtherLiabilitiesCurrent
7000
CY2020Q4 dmac Accrued Taxes And Other Liabilities Current
AccruedTaxesAndOtherLiabilitiesCurrent
8000
CY2021Q1 dmac Income From Governmental Assistance
IncomeFromGovernmentalAssistance
CY2020Q1 dmac Income From Governmental Assistance
IncomeFromGovernmentalAssistance
115000
CY2021Q1 dmac Noncash Lease Expense
NoncashLeaseExpense
14000
CY2020Q1 dmac Noncash Lease Expense
NoncashLeaseExpense
13000
CY2020Q1 dmac Proceeds From Issuance Of Common Stock Net
ProceedsFromIssuanceOfCommonStockNet
7700000
CY2021Q1 dmac Research And Development Incentive Receivable
ResearchAndDevelopmentIncentiveReceivable
289000
CY2020Q4 dmac Research And Development Incentive Receivable
ResearchAndDevelopmentIncentiveReceivable
289000
CY2021Q1 dmac Stock Issued During Period Shares Exercise Of Common Stock Warrants
StockIssuedDuringPeriodSharesExerciseOfCommonStockWarrants
0
CY2021Q1 dmac Working Capital
WorkingCapital
23000000
CY2021Q1 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
420000
CY2020Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
864000
CY2020Q4 us-gaap Assets Current
AssetsCurrent
27921000
CY2021Q1 us-gaap Assets Noncurrent
AssetsNoncurrent
161000
CY2021Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
689000
CY2020Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1099000
CY2021Q1 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
337000
CY2020Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
340000
CY2021Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
420000
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
864000
CY2021Q1 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
48000
CY2020Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
57000
CY2021Q1 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-4000
CY2020Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-2000
CY2021Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
95680000
CY2020Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
94925000
CY2021Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
511000
CY2020Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
393000
CY2021Q1 us-gaap Assets
Assets
24356000
CY2020Q4 us-gaap Assets
Assets
28095000
CY2021Q1 us-gaap Assets Current
AssetsCurrent
24195000
CY2020Q4 us-gaap Assets Noncurrent
AssetsNoncurrent
174000
CY2021Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
3329000
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
7409000
CY2021Q1 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
3300000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
7409000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
3883000
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
3329000
CY2020Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
3300000
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-4080000
CY2020Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-583000
CY2021Q1 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
2808262
CY2021Q1 us-gaap Common Stock No Par Value
CommonStockNoParValue
0
CY2020Q4 us-gaap Common Stock No Par Value
CommonStockNoParValue
0
CY2021Q1 us-gaap Common Stock Shares Authorized Unlimited
CommonStockSharesAuthorizedUnlimited
Unlimited
CY2020 us-gaap Common Stock Shares Authorized Unlimited
CommonStockSharesAuthorizedUnlimited
Unlimited
CY2021Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
18786157
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
18746157
CY2021Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
18786157
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
18746157
CY2021Q1 us-gaap Common Stock Value
CommonStockValue
CY2020Q4 us-gaap Common Stock Value
CommonStockValue
CY2021Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-3624000
CY2020Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-2385000
CY2021Q1 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Concentration of credit risk</div></div></div> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</div> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Financial instruments that potentially expose the Company to concentration of credit risk consist primarily of cash, cash equivalents and marketable securities. The Company maintains its cash balances primarily with <div style="display: inline; font-style: italic; font: inherit;">one</div> financial institution. These balances generally exceed federally insured limits. The Company has <div style="display: inline; font-style: italic; font: inherit;">not</div> experienced any losses in such accounts and believes it is <div style="display: inline; font-style: italic; font: inherit;">not</div> exposed to any significant credit risk in cash and cash equivalents. The Company believes that the credit risk related to marketable securities is limited due to the adherence to an investment policy focused on the preservation of principal.</div></div></div></div></div></div></div></div>
CY2021Q1 us-gaap Depreciation
Depreciation
6000
CY2020Q1 us-gaap Depreciation
Depreciation
6000
CY2021Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.19
CY2020Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.19
CY2021Q1 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
33000
CY2020Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
483000
CY2021Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-410000
CY2020Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
262000
CY2021Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-3000
CY2020Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
162000
CY2021Q1 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
6000
CY2020Q4 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
6000
CY2021Q1 us-gaap Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
5000
CY2020Q4 us-gaap Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
7000
CY2021Q1 us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
2000
CY2020Q1 us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
2000
CY2021Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1213000
CY2020Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1055000
CY2021Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-3615000
CY2020Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-2416000
CY2021Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
7000
CY2020Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
9000
CY2021Q1 us-gaap Income Taxes Receivable
IncomeTaxesReceivable
4000
CY2020Q4 us-gaap Income Taxes Receivable
IncomeTaxesReceivable
2000
CY2021Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-458000
CY2020Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-654000
CY2021Q1 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
383000
CY2020Q1 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
397000
CY2021Q1 us-gaap Investment Income Net Amortization Of Discount And Premium
InvestmentIncomeNetAmortizationOfDiscountAndPremium
-26000
CY2020Q1 us-gaap Investment Income Net Amortization Of Discount And Premium
InvestmentIncomeNetAmortizationOfDiscountAndPremium
14000
CY2021Q1 us-gaap Lessee Operating Lease Discount Rate
LesseeOperatingLeaseDiscountRate
0.09
CY2021Q1 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
97000
CY2021Q1 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
46000
CY2021Q1 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
51000
CY2021Q1 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
6000
CY2021Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
24356000
CY2020Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
28095000
CY2021Q1 us-gaap Liabilities Current
LiabilitiesCurrent
1178000
CY2020Q4 us-gaap Liabilities Current
LiabilitiesCurrent
2028000
CY2021Q1 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
33000
CY2020Q4 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
53000
CY2021Q1 us-gaap Marketable Securities
MarketableSecurities
20100000
CY2021Q1 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
20072000
CY2020Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
20098000
CY2021Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
91000
CY2021Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
63000
CY2020Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
59000
CY2021Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
28000
CY2021Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
242000
CY2020Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
7696000
CY2021Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-9000
CY2020Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-5301000
CY2021Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-4313000
CY2020Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-2978000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-3622000
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
-2425000
CY2021Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
4000
CY2020Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-12000
CY2021Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-3619000
CY2020Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-2404000
CY2021Q1 us-gaap Operating Lease Cost
OperatingLeaseCost
17000
CY2020Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
46000
CY2021Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
86000
CY2020Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
100000
CY2021Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-2000
CY2020Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
40000
CY2021Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
4000
CY2020Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-127000
CY2021Q1 us-gaap Other Receivables
OtherReceivables
44000
CY2020Q4 us-gaap Other Receivables
OtherReceivables
49000
CY2021Q1 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
11923000
CY2020Q1 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
8799000
CY2021Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
9000
CY2020Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
2000
CY2021Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
457000
CY2020Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
74000
CY2020Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
8500000
CY2021Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
CY2020Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
7682000
CY2021Q1 us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
11921000
CY2020Q1 us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
3500000
CY2021Q1 us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
2000
CY2020Q1 us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
CY2021Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
244000
CY2020Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
16000
CY2021Q1 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
123000
CY2020Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
131000
CY2021Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
75000
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
74000
CY2021Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2406000
CY2020Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1349000
CY2021Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-72531000
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-68909000
CY2021Q1 us-gaap Share Based Compensation
ShareBasedCompensation
511000
CY2020Q1 us-gaap Share Based Compensation
ShareBasedCompensation
393000
CY2021Q1 us-gaap Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Exercisable Options
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
1067190
CY2021Q1 us-gaap Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Outstanding Options
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
1421094
CY2021Q1 us-gaap Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Exercisable Options Weighted Average Remaining Contractual Term2
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2
P7Y
CY2021Q1 us-gaap Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Exercise Price Beginning Balance1
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
5.60
CY2021Q1 us-gaap Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Remaining Contractual Term2
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
P7Y182D
CY2020Q1 us-gaap Shares Issued Price Per Share
SharesIssuedPricePerShare
4
CY2021Q1 us-gaap Stock Granted During Period Value Sharebased Compensation
StockGrantedDuringPeriodValueSharebasedCompensation
511000
CY2020Q1 us-gaap Stock Granted During Period Value Sharebased Compensation
StockGrantedDuringPeriodValueSharebasedCompensation
393000
CY2020Q1 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
2125000
CY2021Q1 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
40000
CY2020Q1 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
7200
CY2020Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
7682000
CY2021Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
244000
CY2020Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
16000
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
23145000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
26014000
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
7617000
CY2020Q1 us-gaap Stockholders Equity
StockholdersEquity
13323000
CY2021Q1 us-gaap Variable Lease Cost
VariableLeaseCost
14000
CY2021Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
18766656
CY2020Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
13107725

Files In Submission

Name View Source Status
0001437749-21-010912-index-headers.html Edgar Link pending
0001437749-21-010912-index.html Edgar Link pending
0001437749-21-010912.txt Edgar Link pending
0001437749-21-010912-xbrl.zip Edgar Link pending
dmac-20210331.xml Edgar Link completed
dmac-20210331.xsd Edgar Link pending
dmac-20210331_cal.xml Edgar Link unprocessable
dmac-20210331_def.xml Edgar Link unprocessable
dmac-20210331_lab.xml Edgar Link unprocessable
dmac-20210331_pre.xml Edgar Link unprocessable
dmt01.jpg Edgar Link pending
dmtp20210331_10q.htm Edgar Link pending
ex_246297.htm Edgar Link pending
ex_246298.htm Edgar Link pending
ex_246299.htm Edgar Link pending
ex_246300.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending